On February 17, 2014 Novartis announced the acquisition of CoStim Pharmaceuticals Inc., a Cambridge, MA-based, privately held biotechnology company focused on harnessing the immune system to eliminate immune-blocking signals from cancer (Press release Novartis, FEB 17, 2014, View Source [SID:1234500084]). With this acquisition Novartis is adding late discovery stage immunotherapy programs directed to several targets, including PD-1.
Financial terms are not disclosed.